Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01990950 · ClinicalTrials.gov registry record · NA
Fenestrated AAA Endovascular Graft Post-Approval Study
A NA study, sponsored by Cook Research Incorporated.
- Completed
- Registry status
- NA
- Development phase
- 21
- Enrollment target
NCT01990950: Completed NA study, sponsored by Cook Research Incorporated.
NCT01990950 is a NA study that has completed, run by Cook Research Incorporated. The registered enrollment target is 21 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01990950, a NA study, has completed, sponsored by Cook Research Incorporated.
- COMPLETED
- Registry status
- NA
- Development phase
- 21 participants
- Enrollment target
Study Summary
This post-market study is approved by the US FDA to evaluate the long-term safety and performance of the Zenith® Fenestrated AAA Endovascular Graft.
Primary Outcome
patients treated with the Zenith® Fenestrated AAA Endovascular Graft will have a rate of aneurysm-related mortality at 5 years that meets a performance goal of 18% ,
Interventions
- DEVICE Zenith® Fenestrated AAA Endovascular Graft
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2014-03 |
| Est. Completion | 2020-10-12 |
| Phase | NA |
What the finished NCT01990950 record still lists
NCT01990950 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 21 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower).
The record links to 0 conditions, and to 1 intervention - of which Zenith® Fenestrated AAA Endovascular Graft is the first listed.
NCT01990950 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01990950 about?
NCT01990950 is a clinical study titled "Fenestrated AAA Endovascular Graft Post-Approval Study". This post-market study is approved by the US FDA to evaluate the long-term safety and performance of the Zenith® Fenestrated AAA Endovascular Graft.
What is the current status of trial NCT01990950?
This trial is currently completed. It is a NA study. The enrollment target is 21 participants. The study started on 2014-03. Estimated completion is 2020-10-12.
What interventions are being tested in trial NCT01990950?
The interventions under investigation include: Zenith® Fenestrated AAA Endovascular Graft (DEVICE).
Who is sponsoring clinical trial NCT01990950?
This trial is sponsored by Cook Research Incorporated, which has 24 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01990950's enrollment target sits among peer trials
21 1762nd of 2000 higher than 233 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02447874 · 21 participants · Phase 1
Arginine Therapy for the Treatment of Pain in Children With Sickle Cell Disease
- NCT03826992 · 21 participants · Phase 1
Venetoclax Combined With Vyxeos (CPX-351) for Participants With Relapsed or Refractory Acute Leukemia
- NCT04107077 · 21 participants · Phase 2
Phase II Study of the Effects of Laparoscopic Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Patients With Advanced Gastric Cancer
- NCT04158635 · 21 participants · Phase 1
Gemcitabine, Nab-Paclitaxel, and Bosentan for the Treatment of Unresectable Pancreatic Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia